Hopstem hNPC01 Earns FDA RMAT Designation for Chronic Stroke Therapy

Hopstem Announces FDA Granted iPSC Therapy hNPC01 Injection Fast Track Designation, Accelerating Global Breakthrough in Treatment of Cerebral Neural Injury Diseases

Hopstem Biotechnology at 2024 CASSS CGPT Symposium

Hopstem to Showcase hNPC01 Clinical Data at 2024 ASGCT Annual Meeting in Baltimore

hNPC01, human iPSC-derived human forebrain neural progenitor cell product of Hopstem Biotech has been granted clinical approval treating hemiplegia sequelae after chronic ischemic stroke by FDA

hNPC01, human iPSC-derived human forebrain neural progenitor cell product of Hopstem Biotech has been granted clinical approval treating hemiplegia sequelae after chronic ischemic stroke by CFDA